

DAFTAR PUSTAKA

- AAO, 2002. International Clinical Classification of Diabetic Retinopathy Severity of Diabetic Macular Edema. *American Academi of Ophthalmology*, **October**: .
- AAO, 2016. *Diabetic Retinopathy Preferred Practice Pattern*. San Fransisco.
- ADA, 2018. Standart in Medical Care in Diabetes 2018. *Diabetes Care*, **41**: .
- American Diabetes Association, 2017. Diabetes Care.
- Arikan, G., Saatci, A.O., dan Oner, F.H., 2011. Immediate intraocular pressure rise after intravitreal injection of ranibizumab and two doses of triamcinolone acetone. *International journal of ophthalmology*, **4**: 402.
- Behl, T., Kaur, I., dan Kotwani, A., 2016. Implication of oxidative stress in progression of diabetic retinopathy. *Survey of Ophthalmology*, **61**: 187–196.
- Bhattacharyya, B., 2009. *Step by Step Laser in Ophthalmology*. Jaypee Brothers Medical, New Delhi.
- Bourne, R.R.A., Stevens, G.A., White, R.A., Smith, J.L., Flaxman, S.R., Price, H., dkk., 2013. Causes of vision loss worldwide, 1990-2010: a systematic analysis. *The Lancet. Global Health*, **1**: e339-349.
- Bressler, S.B., Qin, H., Beck, R.W., Chalam, K., Kim, J.E., Melia, M., dkk., 2012. Factors Associated With Changes in Visual Acuity and Central Subfield Thickness at 1 Year After Treatment for Diabetic Macular Edema With Ranibizumab. *Archives of Ophthalmology*, **130**: 1153.
- Browning, D.J. dan Glassman, A.R., 2007. Relationship between Optical Coherence Tomography–Measured Central Retinal Thickness and Visual Acuity in Diabetic Macular Edema. *Ophthalmology*, **114**: 525–536.
- Browning, D.J., Zhang, Z., Benfield, J.M., dan Scott, A.Q., 1997. The effect of patient characteristics on response to focal laser treatment for diabetic macular edema. *Ophthalmology*, **104**: 466–472.
- Chan, A., Duker, J.S., Ko, T.H., Fujimoto, J.G., dan Schuman, J.S., 2006. Normal macular thickness measurements in healthy eyes using Stratus optical coherence tomography. *Archives of ophthalmology*, **124**: 193–198.
- Chew, E.Y., Ambrosius, W.T., Davis, M.D., Danis, R.P., Gangaputra, S., Greven, C.M., dkk., 2010. Effects of medical therapies on retinopathy progression in type 2 diabetes. *The New England Journal of Medicine*, **363**: 233–244.
- Chew, E.Y., Klein, M.L., Ferris, F.L., Remaley, N.A., Murphy, R.P., Chantry, K., dkk., 1996. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. *Archives of Ophthalmology (Chicago, Ill.: 1960)*, **114**: 1079–1084.
- Chu, J. dan Ali, Y., 2008. Diabetic retinopathy: a review. *Drug Development Research*, **69**: 1–14.
- Das, A., McGuire, P.G., dan Rangasamy, S., 2015. Diabetic Macular Edema: Pathophysiology and Novel Therapeutic Targets. *Ophthalmology*, **122**: 1375–1394.

- Dessì, M., Noce, A., Bertucci, P., Manca di Villahermosa, S., Zenobi, R., Castagnola, V., dkk., 2013. Atherosclerosis, Dyslipidemia, and Inflammation: The Significant Role of Polyunsaturated Fatty Acids. *ISRN Inflammation*, **2013**: 1–13.
- Do, D.V., Shah, S.M., Sung, J.U., Haller, J.A., dan Nguyen, Q.D., 2005. Persistent diabetic macular edema is associated with elevated hemoglobin A1c. *American Journal of Ophthalmology*, **139**: 620–623.
- Do, D.V., Wang, X., Vedula, S.S., Marrone, M., Sleilati, G., Hawkins, B.S., dkk., 2015. Blood pressure control for diabetic retinopathy. *Cochrane Database of Systematic Reviews*, .
- Ellis, D., Burgess, P.I., dan Kayange, P., 2013. “Teaching corner”: Management of Diabetic Retinopathy. *Malawi Medical Journal*, **25**: 116–120.
- Falavarjani, K.G. dan Nguyen, Q.D., 2013. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. *Eye*, **27**: 787.
- Feldman-Billard, S., Larger, é., dan Massin, P., 2018. Early worsening of diabetic retinopathy after rapid improvement of blood glucose control in patients with diabetes. *Diabetes & Metabolism*, **44**: 4–14.
- Ferris, F.L. dan Nathan, D.M., 2016. Preventing Diabetic Retinopathy Progression. *Ophthalmology*, **123**: 1840–1842.
- Hassairi, A.E.M., Chebil, A., Abdallah, M.B., Maamouri, R., Chaker, N., dan Matri, L.E., 2015. Correlation of visual acuity and central macular thickness in diabetic macular edema, dalam: *Acta Ophthalmol.*
- Idiculla, J., Nithyanandam, S., Joseph, M., Mohan, V.A., Vasu, U., dan Sadiq, M., 2012. Serum lipids and diabetic retinopathy: a cross-sectional study. *Indian journal of endocrinology and metabolism*, **16**: S492.
- Ioannidou, E., Tseriotis, V.-S., dan Tziomalos, K., 2017. Name of Journal: World Journal of Diabetes ESPS Manuscript NO: 29435 Manuscript Type: Editorial Role of lipid-lowering agents in the management of diabetic retinopathy.
- James, P.A., Oparil, S., Carter, B.L., Cushman, W.C., Dennison-Himmelfarb, C., Handler, J., dkk., 2014. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). *JAMA*, **311**: 507.
- Jew, O.M., Peyman, M., Chen, T.C., dan Visvaraja, S., 2012. Risk factors for clinically significant macular edema in a multi-ethnics population with type 2 diabetes. *International Journal of Ophthalmology*, **5**: 499–504.
- Jones, C.D., Greenwood, R.H., Misra, A., dan Bachmann, M.O., 2012. Incidence and Progression of Diabetic Retinopathy During 17 Years of a Population-Based Screening Program in England. *Diabetes Care*, **35**: 592–596.
- Kajiwara, A., Miyagawa, H., Saruwatari, J., Kita, A., Sakata, M., Kawata, Y., dkk., 2014. Gender differences in the incidence and progression of diabetic retinopathy among Japanese patients with type 2 diabetes mellitus: A clinic-based retrospective longitudinal study. *Diabetes Research and Clinical Practice*, **103**: e7–e10.

- Kaushal, K., New, J.P., McDowell, D., Young, L.B., Taylor, R., dan Young, R.J., 2002. Visual outcome after laser treatment for diabetic retinopathy. *Practical Diabetes International*, **19**: 6–9.
- King, G.L., Blankenship, G., Cavalierano, J.D., dan Ferris III, F.L., 2002. Diabetic Retinopathy. *Diabetes Care*, **24**: s90–s93.
- Koyanagi, Y., Yoshida, S., Kobayashi, Y., Kubo, Y., Nakama, T., Ishikawa, K., dkk., 2018. Visual Outcomes Based on Early Response to Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema. *Ophthalmologica*, **239**: 94–102.
- Kryztolik MG, Strauber SF, Aiello LP, Beck RW, Berger BB, Bressler NM, dkk., 2007. Reproducibility of macular thickness and volume using Zeiss optical coherence tomography in patients with diabetic macular edema. *Ophthalmology*, **114**: 1520–1525.
- Lang, G.E., 2012. Diabetic Macular Edema. *Ophthalmologica*, **227**: 21–29.
- Lee, R., Wong, T.Y., dan Sabanayagam, C., 2015. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. *Eye and Vision*, **2**: .
- Lemeshow S., Hosmer D.W., Klar J., Lwanga S.K., dan Organization W.H., 1990. Adequacy of sample size in health studies.
- Liu, E., Craig, J.E., dan Burdon, K., 2017. Diabetic macular oedema: clinical risk factors and emerging genetic influences: Diabetic macular oedema: risk factors and genetic influences Liu, Craig and Burdon. *Clinical and Experimental Optometry*, **100**: 569–576.
- Lwanga S.K., Lemeshow S., dan Organization W.H., 1991. Sample size determination in health studies : a practical manual.
- Ma, H., 2004. Cholesterol and human health. *Nature and Science*, **2**: 17–21.
- Messina, E. dan Evans, J.M., 2006. Standards for visual acuity. *National Institute for Standards and Technology*, .
- Michaelides, M., Kaines, A., Hamilton, R.D., Fraser-Bell, S., Rajendram, R., Quhill, F., dkk., 2010. A Prospective Randomized Trial of Intravitreal Bevacizumab or Laser Therapy in the Management of Diabetic Macular Edema (BOLT Study). *Ophthalmology*, **117**: 1078–1086.e2.
- Papavasileiou, E., 2015. Role of Anti-VEGF in Diabetic Macular Edema.
- Parth, S., Stephen G, S., dan Ingrid U, S., 2017. Updating Your Diabetic Macular Edema Treatment Protocol. *Retinal Physician*, **14**: 48–50,52,65.
- Romero-Aroca, P., Reyes-Torres, J., Baget-Bernaldiz, M., dan Blasco-Suñe, C., 2014. Laser treatment for diabetic macular edema in the 21st century. *Current diabetes reviews*, **10**: 100–112.
- Sang, D.N. dan D’Amore, P.A., 2008. Is blockade of vascular endothelial growth factor beneficial for all types of diabetic retinopathy? *Diabetologia*, **51**: 1570–1573.
- Schmidt-Erfurth, U., Garcia-Arumi, J., Bandello, F., Berg, K., Chakravarthy, U., Gerendas, B.S., dkk., 2017. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). *Ophthalmologica*, **237**: 185–222.

- Scholl, S., Kirchhof, J., dan Augustin, A.J., 2010. Pathophysiology of Macular Edema. *Ophthalmologica*, **224**: 8–15.
- Singh, R.P., Habbu, K., Ehlers, J.P., Lansang, M.C., Hill, L., dan Stoilov, I., 2016. The Impact of Systemic Factors on Clinical Response to Ranibizumab for Diabetic Macular Edema. *Ophthalmology*, **123**: 1581–1587.
- Soheilian, M., Ramezani, A., Obudi, A., Bijanzadeh, B., Salehipour, M., Yaseri, M., dkk., 2009. Randomized Trial of Intravitreal Bevacizumab Alone or Combined with Triamcinolone versus Macular Photocoagulation in Diabetic Macular Edema. *Ophthalmology*, **116**: 1142–1150.
- Solomon, S.D., Chew, E., Duh, E.J., Sobrin, L., Sun, J.K., VanderBeek, B.L., dkk., 2017. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. *Diabetes Care*, **40**: 412–418.
- Sophie, R., Lu, N., dan Campochiaro, P.A., 2015. Predictors of Functional and Anatomic Outcomes in Patients with Diabetic Macular Edema Treated with Ranibizumab. *Ophthalmology*, **122**: 1395–1401.
- Stefánsson, E., 2009. Diabetic macular edema. *Saudi Journal of Ophthalmology*, **23**: 143–148.
- Stratton, I.M., Kohner, E.M., Aldington, S.J., Turner, R.C., Holman, R.R., Manley, S.E., dkk., 2001. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. *Diabetologia*, **44**: 156–163.
- Tarr, J.M., Kaul, K., Chopra, M., Kohner, E.M., dan Chibber, R., 2013. Pathophysiology of Diabetic Retinopathy. *ISRN Ophthalmology*, **2013**: 1–13.
- Universale, C.O., 1984. Visual acuity measurement standard. *Italian Journal*, .
- Urias, E.A., Urias, G.A., Monickaraj, F., McGuire, P., dan Das, A., 2017. Novel therapeutic targets in diabetic macular edema: Beyond VEGF. *Vision Research*, **139**: 221–227.
- Varma, R., Bressler, N.M., Doan, Q.V., Gleeson, M., Danese, M., Bower, J.K., dkk., 2014. Prevalence of and Risk Factors for Diabetic Macular Edema in the United States. *JAMA Ophthalmology*, **132**: 1334.
- Virgili, G., Parravano, M., Evans, J.R., Gordon, I., dan Lucenteforte, E., 2017. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. *Cochrane Database of Systematic Reviews*, .
- Virgili, G., Parravano, M., Menchini, F., dan Evans, J.R., 2014. Anti-vascular endothelial growth factor for diabetic macular oedema, dalam: The Cochrane Collaboration (Editor), *Cochrane Database of Systematic Reviews*. John Wiley & Sons, Ltd, Chichester, UK.
- Wild, S., Roglic, G., Green, A., Sicree, R., dan King, H., 2004. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. *Diabetes care*, **27**: 1047–1053.
- Wong, T.Y., Mwamburi, M., Klein, R., Larsen, M., Flynn, H., Hernandez-Medina, M., dkk., 2009. Rates of Progression in Diabetic Retinopathy During Different Time Periods: A systematic review and meta-analysis. *Diabetes Care*, **32**: 2307–2313.



UNIVERSITAS
GADJAH MADA

FAKTOR YANG MEMPENGARUHI OUTCOME KLINIK PADA TERAPI RETINOPATI DIABETIK DENGAN EDEMA MAKULA

PENI SUSILOWATI P, Dr. Tri Murti Andayani, Sp.FRS., Apt; dr. Supanji, Sp.M., M.Kes., Ph.D

Universitas Gadjah Mada, 2018 | Diunduh dari <http://etd.repository.ugm.ac.id/>

Zheng, Y., Lamoureux, E.L., Lavanya, R., Wu, R., Ikram, M.K., Wang, J.J., dkk., 2012. Prevalence and Risk Factors of Diabetic Retinopathy in Migrant Indians in an Urbanized Society in Asia. *Ophthalmology*, **119**: 2119–2124.